ClinicalTrials.gg
RecruitingNCT06842875RI-SPHERESUpdated Nov 13, 2026

Rhode Island - Statewide Postpartum Hypertension Remote Surveillance

An interventional study of RI-SPHERES and Standard self-measured blood pressure program in Hypertension in Pregnancy, Postpartum Preeclampsia and Postpartum Complication, sponsored by Women and Infants Hospital of Rhode Island. Recruiting at 5 sites in United States. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Women and Infants Hospital of Rhode Island · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,536
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Hypertension, Pregnancy-Induced with a site in United States — 30 open to participants now, 40 under way, 4 of them phase 3. Hypertension, Pregnancy-Induced · United States.

Planned enrollment
4th of 89
1,536 · median 120
Started
2025
with 9 others
No phase
51 of 106
14 open now
Primary completion
2029-03
later than 33 of 39 live
Registered
93rd of 106
by date

Among the 106 studies in Hypertension, Pregnancy-Induced with a site in United States, this one is the 4th largest by planned enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2025, is one of 51 with no phase, reaches primary completion later than 33 of the 39 other live ones, and was the 93rd registered.

Hypertension, Pregnancy-Induced

262 studies on the registry are indexed under Hypertension, Pregnancy-Induced; 70 are open to participants now.

Browse Hypertension, Pregnancy-Induced studies →

Open to participants now

30 of the 106 studies in Hypertension, Pregnancy-Induced with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Hypertension, Pregnancy-Induced studies recruiting now, 23 (43%) set no upper age limit and 29 (55%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Hypertension, Pregnancy-Induced with a site in United States, or all of them as a file.
02

Study summary

This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.

Read the detailed description

Uncontrolled hypertensive disorders of pregnancy (HDP) are a major source of maternal mortality. National guidelines recommend blood pressure (BP) measurement 3-10 days after discharge and ≥1 preventive care visit within one year of delivery. Yet, barriers such as childcare or transportation issues reduce adherence to in-person BP checks, particularly among racial or ethnic minority patients. Programs in which patients self-measure BP (SMBP) at home show promising results regardless of patient race. However, a recent meta-analysis concluded current SMBP programs do not reduce maternal mortality or racial disparities in clinical outcomes, potentially due to their specific limitations: they end within six weeks of birth (though HDP can persist for months) and have decreased engagement with non-White people or those living in disadvantaged areas, though these populations are at the highest risk of persistent HTN and its adverse long-term effects. Thus, there is an urgent need to optimize SMBP programs to target short- and long-term HDP-related morbidity and to broadly implement these programs to eliminate disparities in HDP-related outcomes. One such program is Rhode Island (RI)-Statewide Postpartum HypErtension REmote Surveillance (RI-SPHERES), a technology-based SMBP program that aims to reduce short- and long-term HDP-associated morbidity in RI using the collaborative care model, a health services intervention that improves health outcomes and reduces racial disparities on a population level for people with chronic conditions. The proposed research aims to determine the effectiveness of RI-SPHERES in reducing short- and long-term morbidity associated with HDP throughout RI. This builds upon our pilot RCT (NCT05595629), in which a standard SMBP program was compared to a SMBP program that used a Bluetooth-enabled BP cuff that syncs to a smartphone application (app) to send automated reminders and provide adaptive messaging tailored to distinct BP values and symptoms. RI-SPHERES will expand this SMBP program to provide app-based patient-informed educational content on HDP-specific preventive care and bidirectional communication with RI-SPHERES staff for one year postpartum. Incorporating adaptive and automatic messaging increases RI-SPHERES' scalability by reducing clinical staff burden. However, formal analysis of factors that may hinder widespread implementation of RI-SPHERES is needed. Thus, we will conduct a Hybrid Type I Non-Inferiority Implementation-Effectiveness Trial among 1536 patients with HDP that compares a standard SMBP program to RI-SPHERES in terms of persistent HTN at six weeks postpartum and receipt of preventive care within one year of delivery (Specific Aim 1). We will examine the effect of both programs on increasing equity in terms of race, ethnicity, language, and geography for postpartum patients with HDP in Rhode Island (Specific Aim 2). We will also develop an implementation toolkit to facilitate the dissemination of RI-SPHERES (Specific Aim 3). The proposed project is expected to deliver a mechanism that will fill multiple research gaps for HDP identified by the US Preventive Services Task Force: 1) addressing health inequities through multilevel interventions, 2) evaluating SMBP programs; and 3) mitigating HDP's short- and long-term health consequences of HDP.

03

Conditions studied

  • Hypertension in Pregnancy
  • Postpartum Preeclampsia
  • Postpartum Complication

Keywords

  • postpartum hypertensive disorders of pregnancy
  • postpartum preeclampsia
  • digital health
  • collaborative care model
  • population health
  • self-measured blood pressure
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postpartum patient aged 18 years or more at any birthing hospital in Rhode Island
  • Diagnosed during pregnancy or after delivery with hypertensive disorder of pregnant
  • English-, Spanish-, Portuguese-, or Haitian-Creole-speaking
  • Smartphone ownership

Exclusion criteria

Exclusion Criteria:

  • Prior enrollment in this trial
  • Prisoners or incarcerated people
  • Inability or unwillingness to provide
  • Inability to communicate with study team, despite an interpreter
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
1,536 participants (estimated)

Study arms

  • Experimental
    RI-SPHERES

    A technology enabled collaborative care model. Participants will receive a LTE-enabled blood pressure (BP) cuff that syncs to a smartphone application (app) to send automated reminders and provide adaptive messaging tailored to distinct BP values and symptoms. The first six weeks of the program will focus on BP control, and the remaining time will help transition people to receive recommended preventive care. As part of the collaborative care model, the nurse practitioner will lead weekly meetings with a multidisciplinary clinical team about all enrolled people.

    Behavioral: RI-SPHERES

  • Active comparator
    Standard self-measured blood pressure program

    Our hospital has a remote hypertension monitoring program that recommends daily blood pressure ascertainment for 6 weeks, at which time they are discharged and provided printed resources to encourage preventive care in the next few months. In this program, patients manually enter their self-measured BPs into the electronic medical record for the clinical team to manually review and respond.

    Behavioral: Standard self-measured blood pressure program

Interventions

  • BehavioralRI-SPHERES

    Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.

  • BehavioralStandard self-measured blood pressure program

    Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.

06

What researchers measure

Primary outcomes

  1. Persistent hypertension

    Persistent stage II hypertension will be defined as systolic blood pressure of 140 mmHg or higher and/or diastolic blood pressure of 90 mmHg or higher

    Time frame: Six weeks postpartum

Secondary outcomes

  1. Attendance of preventive care visit

    Participant attends a non-urgent appointment during which an internal medicine physician, family medicine physician, or primary care advanced practice provider (APP, including nurse practitioners or physician assistants) ascertains BP and provides patient counseling pertaining to HTN. While obstetrician-gynecologists (OBGYNs) or certified nurse midwives (CNMs) can provide preventive care, for this aim, visits provided by an OBGYN or CNM will only qualify if the visit occurs ≥6 weeks postpartum and the medical record states that HTN was discussed in the visit.

    Time frame: From six weeks postpartum until one year postpartum

  2. Blood pressure ascertainment

    Participant measured any BP (either in-person or via self-measured blood pressure)

    Time frame: 1-10 days after hospital discharge

  3. Total number of self-measured blood pressure assessments provided to program in immediate postpartum period

    Number of blood pressures sent in to the participant's self-measured blood pressure program (RI-SPHERES or standard program)

    Time frame: Hospital discharge to six weeks postpartum

  4. Total number of self-measured blood pressure assessments provided to program after six weeks postpartum

    Number of blood pressures sent in to the participant's self-measured blood pressure program (RI-SPHERES or standard program)

    Time frame: Six weeks postpartum until one year postpartum

  5. Severe maternal morbidity after hospital discharge

    Severe maternal morbidity, as defined by the Centers for Disease Control's composite.

    Time frame: Hospital discharge until 6 weeks postpartum

  6. Persistent stage I hypertension

    Systolic blood pressure between 130-139 mmHg and/or diastolic blood pressure between 80-89 mmHg

    Time frame: Six weeks, six months, and 12 months postpartum

  7. Persistent stage II hypertension

    Systolic blood pressure at or above 140 mmHg and/or diastolic blood pressure at or above 90 mmHg

    Time frame: Six and 12 months postpartum

  8. Severe hypertension after hospital discharge

    Systolic blood pressure at or above 160 mmHg or diastolic blood pressure at or above 110 mmHg on two or more occasions

    Time frame: Hospital discharge to 6 weeks postpartum

  9. Emergency room visit for hypertension-related etiology

    Presentation to emergency room for hypertension-related chief complaint

    Time frame: Hospital discharge to 6 weeks postpartum

  10. Readmission to inpatient hospital for hypertension-related etiology

    Readmission to inpatient hospital for hypertension-related chief complaint

    Time frame: Hospital discharge until 6 weeks postpartum

  11. Initiation or titration of antihypertension medication

    Initiation or increase in dose titration of antihypertensive medication(s)

    Time frame: Hospital discharge to 6 weeks postpartum

  12. Postpartum visit attendance

    Attendance to the recommended in-person postpartum visit

    Time frame: Four to six weeks postpartum

  13. System usability scale

    A 10-question survey designed to provide a global view of subjective assessments of usability for a technology-based program or intervention

    Time frame: Six weeks, six months, and 12 months postpartum

  14. Client satisfaction questionnaire

    A survey designed to provide an overview of individual satisfaction with a program or intervention

    Time frame: Six weeks, six months, and 12 months postpartum

07

Study locations

3 of 5 sites recruiting
  • Newport Hospital
    Newport, Rhode Island 02840, United States
    Not yet recruiting
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02903, United States
    Recruiting
    • Stephanie Nunez, BS · Contactsnunez@wihri.org · 401-274-1122
    • Adam Lewkowitz, MD, MPHS · Principal investigator
  • South County Hospital
    Wakefield, Rhode Island 02879, United States
    Not yet recruiting
  • Kent Hospital
    Warwick, Rhode Island 02886, United States
    Recruiting
    • Jen Buckley, MD · ContactJBuckley@carene.org · 401-227-3669
    • Caroline Richardson, MD · Principal investigator
  • Landmark Hospital
    Woonsocket, Rhode Island 02895, United States
    Recruiting
08

References and documents

Publications

  • Nunez SD, Spratt LM, Ware CF, Machado S, Rousseau J, Jackson TL, Buckley J, Magee S, Wohler D, Blosser E, Sales S, Simmons D, Ramos VN, Castillo MM, Murray C, Bailey K, Gutman R, Richardson CR, Grobman WA, Hauspurg A, Miller ES, Tuuli MG, Lewkowitz AK. Protocol for a type 1 hybrid effectiveness implementation trial to evaluate whether a technology-based collaborative care model is non-inferior to remote blood pressure monitoring on persistent hypertension and preventive care attendance among postpartum people with hypertension. Contemp Clin Trials. 2025 Dec;159:108114. doi: 10.1016/j.cct.2025.108114. Epub 2025 Oct 23. PubMed 41139061 ↗

Individual participant data

Plan to share: Yes — Data will be collected from human subjects and will be shared according to NIH guidelines. The investigators are committed to the sharing of final data, being mindful that the rights and privacy of people who participate in research must be protected at all times. The investigators will make a complete study dataset available for sharing. The investigators will have a description of study dataset, including code books, meta-data related to the dataset, and documented programming code used for creating the final study population, for creating variables, and for conducting all outcomes analyses. The investigators will remain HIPAA compliant, and therefore any datasets resulting from participants will be free of any identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of individual subjects.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 5 years after completion of study

Access criteria: The investigators will make the data and associated documentation available to users under a data-sharing agreement that provides for commitment to: a) using the data only for research purposes and not to identify any individual participant; b) securing the data using appropriate computer technology; and c) destroying or returning the data after analyses are completed. Timelines for distribution of data will vary depending on any required restrictions as mentioned above. Data may be distributed by a number of electronic methods, including web-based databases, datasets, and spreadsheets, or via electronic media such as compact discs.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2029, 46 months after the start.

Of 91 non-industry interventional studies with no phase under Hypertension, Pregnancy-Induced, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 46 months is above that.

Counting every sponsor, half of 92 studies reached it within 24 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 24, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41139061 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41139061 ↗
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06842875
Lead sponsor
Women and Infants Hospital of Rhode Island
Collaborators
Brown University, Kent Hospital, Rhode Island
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Apr 15, 2025
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Stephanie Nunez, Research Coordinator
Contact
snunez@wihri.org
401-274-1122

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion